Supreme Court Temporarily Restores Mail-Order Access to Abortion Pill Mifepristone
The U.S. Supreme Court has issued a temporary stay, reinstating mail-order access to the abortion pill mifepristone until at least May 11, following a recent appeals court ruling that had restricted its distribution.
On Monday, the U.S. Supreme Court temporarily reinstated mail-order access to the abortion pill mifepristone, pausing a recent decision by the 5th U.S. Circuit Court of Appeals that had imposed new restrictions on the drug's distribution. Justice Samuel Alito issued the administrative stay, which will remain in effect until at least May 11, allowing the Court time to consider further action.
The 5th Circuit's ruling had required mifepristone to be dispensed only in person at clinics, effectively blocking its availability via telehealth and mail. This decision was challenged by pharmaceutical companies Danco Laboratories and GenBioPro, who argued that the restrictions would severely limit access to the medication.
Mifepristone, approved by the FDA in 2000, is commonly used in combination with misoprostol for early-stage abortions and miscarriage management. The Supreme Court's temporary stay preserves the status quo, allowing patients to obtain the drug through telehealth consultations and mail delivery while legal proceedings continue.
The case originated from a lawsuit filed by Louisiana's attorney general, challenging the FDA's regulations that permitted mail distribution of mifepristone. The outcome of this legal battle could have significant implications for abortion access nationwide, particularly in states with restrictive abortion laws.